Loading articles...
Elecoglipron Oral GLP-1 Reduces Glucose, Weight in Phase 2
Elecoglipron, an investigational oral GLP-1 receptor agonist, demonstrated reductions in HbA1c and body weight in phase 2 trials.
GLP-1 Receptor Agonist Use Varies Widely for Youth Type 2 Diabetes
Geographic variation in GLP-1 receptor agonist prescribing for youths with type 2 diabetes across the US highlights disparities in care.
Combination GLP-1RA and SGLT2i May Offer Additive Benefits in T2DM
Combination therapy with GLP-1RAs and SGLT2i may provide additive benefits in type 2 diabetes, particularly for cardiovascular and renal outcomes.
Omnipod 5 Improves CGM Metrics, Reduces Hypoglycaemia in Diabetes
A real-world study of the Omnipod 5 automated insulin delivery system showed improvements in time in range and reduced hypoglycaemia.
Novel Therapies Target Atherogenic Lp(a) Particle
Emerging therapeutic strategies are shifting focus from LDL cholesterol to apoB, targeting Lp(a) and other atherogenic particles.
MAHA Faces Rural Health Gaps: Infrastructure and Workforce Deficits
Microangiopathic hemolytic anemia (MAHA) presents diagnostic and management challenges in rural settings due to limited resources and specialist access.
Microbiome's Role in Lupus: A Policy and Therapeutic 'Frame Shift'
New perspectives on the gut microbiome's influence on systemic lupus erythematosus (SLE) necessitate a re-evaluation of health policy and therapeutic strategies.
HHS Proposes Plan to Accelerate Clinical Trial Timelines
The US Department of Health and Human Services (HHS) has outlined a strategy to expedite clinical trials, aiming to reduce development times for new therapies.
New Glaucoma Care Restriction: IOP Targets and Treatment Access
A recent policy change limiting glaucoma treatment options warrants scrutiny, potentially impacting intraocular pressure management and patient outcomes.